ChromaDex (NASDAQ:CDXC) Stock Rating Lowered by StockNews.com

ChromaDex (NASDAQ:CDXC - Get Free Report) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating in a research note issued on Friday.

A number of other research analysts have also recently weighed in on CDXC. Roth Mkm lifted their target price on ChromaDex from $6.00 to $8.00 and gave the company a "buy" rating in a report on Wednesday, November 6th. HC Wainwright lifted their price objective on ChromaDex from $6.00 to $8.00 and gave the company a "buy" rating in a research note on Monday, November 4th.

ChromaDex Trading Up 0.5 %

Shares of NASDAQ CDXC traded up $0.03 on Friday, reaching $5.51. 332,655 shares of the company traded hands, compared to its average volume of 399,378. The stock has a market capitalization of $420.87 million, a PE ratio of 551.55 and a beta of 2.15. ChromaDex has a fifty-two week low of $1.36 and a fifty-two week high of $7.97. The company has a 50 day moving average of $6.29 and a 200 day moving average of $4.24.

ChromaDex (NASDAQ:CDXC - Get Free Report) last issued its quarterly earnings results on Thursday, October 31st. The company reported $0.02 EPS for the quarter. The firm had revenue of $25.58 million during the quarter, compared to analyst estimates of $23.70 million. ChromaDex had a net margin of 1.62% and a return on equity of 4.85%. During the same quarter in the prior year, the business posted ($0.01) earnings per share. As a group, research analysts expect that ChromaDex will post 0.04 earnings per share for the current year.

Insider Activity

In other news, Director Frank L. Jaksch, Jr. sold 37,161 shares of the stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $6.19, for a total value of $230,026.59. Following the completion of the sale, the director now owns 244,179 shares in the company, valued at approximately $1,511,468.01. This trade represents a 13.21 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 9.64% of the company's stock.

Hedge Funds Weigh In On ChromaDex

A number of institutional investors and hedge funds have recently bought and sold shares of CDXC. WINTON GROUP Ltd acquired a new position in shares of ChromaDex during the second quarter worth $597,000. Bank of New York Mellon Corp increased its stake in ChromaDex by 170.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 190,442 shares of the company's stock worth $520,000 after buying an additional 119,915 shares during the period. BSW Wealth Partners acquired a new position in ChromaDex in the 3rd quarter worth $324,000. BNP Paribas Financial Markets boosted its position in ChromaDex by 1,885.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 73,272 shares of the company's stock valued at $267,000 after buying an additional 69,582 shares during the last quarter. Finally, State Street Corp grew its stake in shares of ChromaDex by 11.3% during the third quarter. State Street Corp now owns 618,028 shares of the company's stock valued at $2,256,000 after acquiring an additional 62,692 shares in the last quarter. Hedge funds and other institutional investors own 15.41% of the company's stock.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.